Replies to post #6636 on Tenax Therapeutics Inc (TENX)

[skyticket1]

- Levosimendan is an approved drug in around 55 countries worldwide.

- Duke University’s Duke Clinical Research Institute, (DCRI) to conduct the Phase 3 trial of the Company’s newly acquired compound, levosimendan

- The United States Food and Drug Administration (FDA) has granted Fast Track status for levosimendan

- OXBT has been notified recently by the U.S. Food and Drug Administration (the “FDA”) that the agency has completed its review of the September 2013 nonclinical submission and has lifted the clinical hold on Oxycyte®.

- ongoing clinical trial in traumatic brain injury (TBI) is a double-blind, placebo–controlled, dose-escalation study.

- the Company received net proceeds of approximately $55.0 million

- New Management - new company guidance - Oxygen Biotherapeutics Closes the Acquisition of Phyxius Pharma Assets Related to Levosimendan; John Kelley Appointed CEO of Oxygen Biotherapeutics

Past is past and the future is bright, for everyone his own opinion but somebody would say all the above are lies and fluffy grams.
Time will tell and some will be right and some will be wrong.

[elviscobain2000]

Under your thesis the $61 million is worth nothing. Levosimendan is phase III fast track, you left that out.